The same authors stated that the cancer preventing effects of mTOR inhibitors mainly concerns non-melanoma skin cancers and Kaposi sarcomas, both represented just 10% of our underlying malignant diseases. Here, MTOR is linked to non-melanoma skin carcinoma.